Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-921355 effect on corticospinal excitability in healthy participants
NL-OMON61090Phase 1Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of NBI-921355 in epilepsy, sponsored by Neurocrine Biosciences. Started May 2026; status: recruiting.
02
Drugs
NBI-921355
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON61090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61090.